RECRUITING

Neuroplasticity Biomarkers in Aphasia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.

Official Title

Genetic and MRI Biomarkers of Neuroplasticity Predict Aphasia Recovery and Phenotypes

Quick Facts

Study Start:2025-03-17
Study Completion:2029-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06471127

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Ages 40-90
  2. 2. Right-handed (prior to stroke)
  3. 3. Proficient English speakers
  4. 4. History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
  5. 5. Presence of aphasia (Aims 2-3)
  6. 6. Capacity to understand the nature of the study and provide informed consent
  7. 7. Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment
  8. 8. Medically stable
  1. 1. History of significant medical or neurological disorder (other than stroke)
  2. 2. History of significant or poorly controlled psychiatric disorders
  3. 3. Current abuse of alcohol or drugs, prescription or otherwise
  4. 4. Clinically significant and uncorrected vision or hearing loss
  5. 5. Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin

Contacts and Locations

Study Contact

Haley Dresang, PhD
CONTACT
(608) 890-0628
hdresang@wisc.edu

Principal Investigator

Haley Dresang, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

UW School of Medicine and Public Health
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Haley Dresang, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-17
Study Completion Date2029-05-31

Study Record Updates

Study Start Date2025-03-17
Study Completion Date2029-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Aphasia
  • Language
  • Stroke